Catheter Precision announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company’s intellectual property strategy.

Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK’s technology over existing prior art. The allowed claims protect both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational component of the Company’s platform.

The patented system incorporates a differentiated design enabling precise control of suture tension and pressure application after vascular procedures, supporting effective hemostasis. By securing protection over both structural and functional elements of the technology, VTAK is establishing meaningful barriers to entry and reinforcing its competitive position in complex procedural markets.

“This milestone further underscores Catheter Precision’s commitment to innovation and strengthens its foundation for driving significant long-term shareholder value,” said David A. Jenkins, Chief Executive Officer of Catheter Precision. He continued, “VTAK continues to execute on its strategy of developing differentiated, high-impact medical technologies supported by strong intellectual property protection, positioning the Company for sustained growth and long-term value creation.”

This milestone represents a critical step in building a scalable, IP-driven medical technology platform. The Company believes its expanding patent portfolio will play a key role in supporting long-term commercialisation, product development, and potential strategic opportunities.